Approaching a therapeutic inflection point for FLT3 -mutated AML Available to Purchase

2.

Stone

RM

,

Mandrekar

SJ

,

Sanford

BL

, et al.

Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation

.

N Engl J Med

.

2017

;

377

(

5

):

454

-

464

.

3.

Voso

MT

,

Larson

RA

,

Jones

D

, et al.

Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial

.

Blood Adv

.

2020

;

4

(

19

):

4945

-

4954

.

4.

Frohling

S

,

Schlenk

RF

,

Breitruck

J

, et al.

Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm

.

Blood

.

2002

;

100

(

13

):

4372

-

4380

.

5.

Dohner

H

,

Wei

AH

,

Appelbaum

FR

, et al.

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

.

Blood

.

2022

;

140

(

12

):

1345

-

1377

.

6.

Papaemmanuil

E

,

Gerstung

M

,

Bullinger

L

, et al.

Genomic classification and prognosis in acute myeloid leukemia

.

N Engl J Med

.

2016

;

374

(

23

):

2209

-

2221

.

7.

Thol

F

,

Kolking

B

,

Damm

F

, et al.

Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations

.

Genes Chromosomes Cancer

.

2012

;

51

(

7

):

689

-

695

.

8.

Faham

M

,

Zheng

J

,

Moorhead

M

, et al.

Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia

.

Blood

.

2012

;

120

(

26

):

5173

-

5180

.

9.

Logan

AC

,

Vashi

N

,

Faham

M

, et al.

Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival

.

Biol Blood Marrow Transplant

.

2014

;

20

(

9

):

1307

-

1313

.

10.

Grob

T

,

Sanders

MA

,

Vonk

CM

, et al.

Prognostic value of FLT3-internal tandem duplication residual disease in acute myeloid leukemia

.

J Clin Oncol

.

2023

;

41

(

4

):

756

-

765

.

11.

Loo

S

,

Roberts

AW

,

Anstee

NS

, et al.

Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG

.

Blood

.

2023

;

142

(

23

):

1960

-

1971

.

12.

Perl

A

,

Erba

HP

,

Montesinos

P

, et al.

Quantum-first trial: FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)-specific measurable residual disease (MRD) clearance assessed through induction (IND) and consolidation (CONS) is associated with improved overall survival (OS) in newly diagnosed (nd) FLT3-ITD+ AML patients (pts)

.

Blood

.

2023

;

142

(

suppl 1

):

832

.

13.

Rücker

FG

,

Bullinger

L

,

Cocciardi

S

, et al.

Next-generation sequencing-based measurable residual disease monitoring in acute myeloid leukemia with FLT3 internal tandem duplication treated with intensive chemotherapy plus midostaurin

.

HemaSphere

.

2023

;

7

(

S3

):

e29390a29398

.

14.

Loo

S

,

Dillon

R

,

Ivey

A

, et al.

Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome

.

Blood

.

2022

;

140

(

22

):

2407

-

2411

.

15.

Dillon

LW

,

Gui

G

,

Ravindra

N

, et al.

Measurable residual FLT3 internal tandem duplication before allogeneic transplant for acute myeloid leukemia

.

JAMA Oncol

.

2024

;

10

(

8

):

1104

-

1110

.

16.

Levis

MJ

,

Hamadani

M

,

Logan

B

, et al.

Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3

.

J Clin Oncol

.

2024

;

42

(

15

):

1766

-

1775

.

17.

Othman

J

,

Potter

N

,

Ivey

A

, et al.

Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission

.

Blood

.

2024

;

143

(

19

):

1931

-

1936

.

18.

Wang

ES

,

Montesinos

P

,

Minden

MD

, et al.

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy

.

Blood

.

2022

;

140

(

17

):

1845

-

1857

.

19.

Larson

RA

,

Mandrekar

SJ

,

Huebner

LJ

, et al.

Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial

.

Leukemia

.

2021

;

35

(

9

):

2539

-

2551

.

20.

Sekeres

MA

,

Montesinos

P

,

Patkowska

E

, et al.

QuANTUM-First: efficacy in newly diagnosed patients with FMS-like tyrosine kinase 3-internal tandem duplication–positive (FLT3-ITD+) acute myeloid leukemia (AML) who received continuation therapy

.

HemaSphere

.

2024

;

8

(

S1

):

S142

.

21.

Dohner

H

,

Wei

AH

,

Roboz

GJ

, et al.

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine

.

Blood

.

2022

;

140

(

15

):

1674

-

1685

.

22.

Smith

CC

,

Lin

K

,

Stecula

A

,

Sali

A

,

Shah

NP

.

FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors

.

Leukemia

.

2015

;

29

(

12

):

2390

-

2392

.

23.

Weisberg

E

,

Boulton

C

,

Kelly

LM

, et al.

Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412

.

Cancer Cell

.

2002

;

1

(

5

):

433

-

443

.

24.

Zarrinkar

PP

,

Gunawardane

RN

,

Cramer

MD

, et al.

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

.

Blood

.

2009

;

114

(

14

):

2984

-

2992

.

25.

Pratz

KW

,

Cherry

M

,

Altman

JK

, et al.

Gilteritinib in Combination with induction and consolidation chemotherapy and as maintenance therapy: a phase IB study in patients with newly diagnosed AML

.

J Clin Oncol

.

2023

;

41

(

26

):

4236

-

4246

.

26.

Wang

ES

,

Goldberg

AD

,

Tallman

M

, et al.

Crenolanib and intensive chemotherapy in adults with newly diagnosed FLT3-mutated AML

.

J Clin Oncol

.

2024

;

42

(

15

):

1776

-

1787

.

27.

Schlenk

RF

,

Dohner

K

,

Krauter

J

, et al.

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia

.

N Engl J Med

.

2008

;

358

(

18

):

1909

-

1918

.

28.

Meshinchi

S

,

Arceci

RJ

,

Sanders

JE

, et al.

Role of allogeneic stem cell transplantation in FLT3/ITD-positive AML

.

Blood

.

2006

;

108

(

1

):

400

-

401

.

29.

Schlenk

RF

,

Kayser

S

,

Bullinger

L

, et al.

Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation

.

Blood

.

2014

;

124

(

23

):

3441

-

3449

.

30.

Gale

RE

,

Hills

R

,

Kottaridis

PD

, et al.

No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials

.

Blood

.

2005

;

106

(

10

):

3658

-

3665

.

31.

Dohner

K

,

Thiede

C

,

Jahn

N

, et al.

Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia

.

Blood

.

2020

;

135

(

5

):

371

-

380

.

32.

Ivey

A

,

Hills

RK

,

Simpson

MA

, et al.

Assessment of minimal residual disease in standard-risk AML

.

N Engl J Med

.

2016

;

374

(

5

):

422

-

433

.

33.

Perl

AE

,

Martinelli

G

,

Cortes

JE

, et al.

Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML

.

N Engl J Med

.

2019

;

381

(

18

):

1728

-

1740

.

34.

Daver

N

,

Perl

AE

,

Maly

J

, et al.

Venetoclax plus gilteritinib for FLT3-mutated relapsed/refractory acute myeloid leukemia

.

J Clin Oncol

.

2022

;

40

(

35

):

4048

-

4059

.

35.

Short

NJ

,

Daver

N

,

Dinardo

CD

, et al.

Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-mutated AML

.

J Clin Oncol

.

2024

;

42

(

13

):

1499

-

1508

.

36.

Dohner

K

,

Schlenk

RF

,

Habdank

M

, et al.

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations

.

Blood

.

2005

;

106

(

12

):

3740

-

3746

.

37.

Pratcorona

M

,

Brunet

S

,

Nomdedeu

J

, et al.

Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy

.

Blood

.

2013

;

121

(

14

):

2734

-

2738

.

38.

Dohner

H

,

Estey

E

,

Grimwade

D

, et al.

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

.

Blood

.

2017

;

129

(

4

):

424

-

447

.

39.

Brunner

AM

,

Li

S

,

Fathi

AT

, et al.

Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission

.

Br J Haematol

.

2016

;

175

(

3

):

496

-

504

.

40.

Xuan

L

,

Wang

Y

,

Huang

F

, et al.

Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial

.

Lancet Oncol

.

2020

;

21

(

9

):

1201

-

1212

.

41.

Burchert

A

,

Bug

G

,

Fritz

LV

, et al.

Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN)

.

J Clin Oncol

.

2020

;

38

(

26

):

2993

-

3002

.

42.

Bazarbachi

A

,

Labopin

M

,

Battipaglia

G

, et al.

Allogeneic stem cell transplantation for FLT3-mutated acute myeloid leukemia: in vivo T-cell depletion and posttransplant sorafenib maintenance improve survival. A Retrospective Acute Leukemia Working Party-European Society for Blood and Marrow Transplant Study

.

Clin Hematol Int

.

2019

;

1

(

1

):

58

-

74

.

43.

Schlenk

RF

,

Weber

D

,

Fiedler

W

, et al.

Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD

.

Blood

.

2019

;

133

(

8

):

840

-

851

.

44.

Erba

HP

,

Dombret

H

,

Perl

A

, et al.

Quantum-first: safety by treatment phase and by age in newly diagnosed (nd) patients (pts) with FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) positive acute myeloid leukemia (AML)

.

Blood

.

2023

;

142

(

suppl 1

). 972.

45.

DiNardo

CD

,

Jonas

BA

,

Pullarkat

V

, et al.

Azacitidine and venetoclax in previously untreated acute myeloid leukemia

.

N Engl J Med

.

2020

;

383

(

7

):

617

-

629

.

46.

Konopleva

M

,

Thirman

MJ

,

Pratz

KW

, et al.

Impact of FLT3 mutation on outcomes after venetoclax and azacitidine for patients with treatment-naive acute myeloid leukemia

.

Clin Cancer Res

.

2022

;

28

(

13

):

2744

-

2752

.

47.

Dohner

H

,

Pratz

KW

,

DiNardo

CD

, et al.

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine

.

Blood

.

2024

;

144

(

21

):

2211

-

2222

.

48.

Dennis

M

,

Thomas

IF

,

Ariti

C

, et al.

Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients

.

Blood Adv

.

2021

;

5

(

24

):

5621

-

5625

.

49.

Maiti

A

,

DiNardo

CD

,

Daver

NG

, et al.

Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia

.

Blood Cancer J

.

2021

;

11

(

2

):

25

.

50.

Yilmaz

M

,

Kantarjian

HM

,

Muftuoglu

M

, et al.

Quizartinib with decitabine +/– venetoclax is highly active in patients (Pts) with FLT3-ITD mutated (mut) acute myeloid leukemia (AML): clinical report and signaling Cytof profiling from a phase IB/II trial

.

Blood

.

2020

;

136

(

suppl 1

):

19

-

20

.

51.

Chua

CC

,

Reynolds

J

,

Enjeti

AK

, et al.

An Australasian Leukemia Lymphoma Group (ALLG) phase 2 study to investigate novel triplets to extend remission with venetoclax in elderly (INTERVENE) acute myeloid leukemia

.

Blood

.

2021

;

138

(

suppl 1

):

368

.

52.

Luskin

MR

,

Lee

JW

,

Fernandez

HF

, et al.

Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups

.

Blood

.

2016

;

127

(

12

):

1551

-

1558

.

53.

Burnett

AK

,

Russell

NH

,

Hills

RK

;

United Kingdom National Cancer Research Institute Acute Myeloid Leukemia Study Group

.

Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia

.

Blood

.

2016

;

128

(

3

):

449

-

452

.

54.

Jabbour

E

,

Short

NJ

,

Ravandi

F

, et al.

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study

.

Lancet Haematol

.

2018

;

5

(

12

):

e618

-

e627

.

55.

Foa

R

,

Bassan

R

,

Vitale

A

, et al.

Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults

.

N Engl J Med

.

2020

;

383

(

17

):

1613

-

1623

.

56.

Jabbour

E

,

Short

NJ

,

Jain

N

, et al.

Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial

.

Lancet Haematol

.

2023

;

10

(

1

):

e24

-

e34

.